Metastatic breast cancer trials in Sweden

In Sweden 13 Also abroad 610

13 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
Where
Goteborg
Age
18 years and over
People
90 worldwide
Run by
Delcath Systems Inc.
See details and how to joinNCT06875128 · EU 2025-521966-91-00
Phase 3Taking people
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Where
Goteborg, Stockholm
Age
18 years and over
People
400 worldwide
Run by
Pfizer
See details and how to joinNCT07062965 · EU 2025-520566-22-00
Phase 3Taking people
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Where
Borås, Stockholm, Uppsala
Age
18 years and over
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06312176 · EU 2023-504918-29-00
Phase 1/2Taking people
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Where
Lund, Stockholm
Age
18 years to 130 years
People
695 worldwide
Run by
AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00
Phase 3Taking people
Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer
Where
Gothenburg, Jönköping, Malmö, Örebro, Stockholm, Umeå
Age
18 years and over
People
345 worldwide
Run by
Vastra Gotaland Region
See details and how to joinNCT05377047
Phase 1Taking people
A First-in-Human phase 1, open-label, two-stage, randomized trial to assess the safety, tolerability, and biodistribution of [177Lu]Lu-ABY-271 in tumors and critical organs in subjects with HER2-positive metastatic breast cancer
Where
Goteborg, Huddinge, Uppsala
Age
18 years and over
People
30 worldwide
Run by
Affibody AB
See details and how to join2024-518360-13-00 · EU 2024-518360-13-00
No phaseTaking people
DESTINY Breast Respond HER2-(Ultra)Low Europe
Where
Eskilstuna, Gävle, Jönköping, Örebro, Stockholm, Sundsvall, Umeå, Västerås
Age
18 years and over
People
2,295 worldwide
Run by
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
See details and how to joinNCT05945732
No phaseTaking people
AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.
Where
Gothenburg, Jönköping
Age
18 years and over
People
1,000 worldwide
Run by
Jules Bordet Institute
See details and how to joinNCT02102165
Phase 4Taking people
IMPlementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older bReasT cAncer patieNTs – a pragmatic randomized-controlled trial (IMPORTANT trial)
Where
Orebro, Uppsala
Age
65 years and over
People
495 worldwide
Run by
Region Oerebro Laen
See details and how to join2023-506620-87-00 · EU 2023-506620-87-00
No phaseTaking people
HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC
Where
Solna
Age
18 years and over
People
70
Run by
Renske Altena
See details and how to joinNCT06830382 · EU 2024-512721-89-00
Phase 1Taking people
A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer
Where
Gothenburg, Stockholm, Uppsala
Age
18 years and over
People
21
Run by
Affibody
See details and how to joinNCT07081555
No phaseTaking people
Sweden Cancerome Analysis Network - Breast Recurrence (SCAN-B-rec)
Where
Lund
Age
18 years and over
People
2,000
Run by
Lund University Hospital
See details and how to joinNCT03758976
Phase 3Taking people
Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients
Where
Örebro, Uppsala
Age
70 years and over
People
495 worldwide
Run by
Region Örebro County
See details and how to joinNCT06044623